

IN THE CLAIMS:

1-104. (Cancelled)

105. (**Currently Amended**) ~~[[The]]~~ A method of treating neoplastic disease in a human or animal patient comprising administering to the patient an anti-neoplastic effective amount of a ~~according to Claim 93 wherein the composition comprising~~ comprises as the sole pharmaceutically active components:

- (a) copper gluconate or copper orotate ~~a pharmaceutically acceptable source of assimilable copper;~~
- (b) sodium salicylate ~~salicylic acid or an alkali or alkaline earth metal salt thereof;~~
- (c) vitamin C;
- (d) manganese gluconate or manganese orotate ~~a physiologically acceptable source of assimilable manganese;~~ and optionally one or more of:
- (e) iron gluconate or iron orotate ~~a physiologically acceptable source of assimilable iron;~~
- (f) sublimed ~~a physiologically acceptable source of assimilable~~ sulphur;
- and
- (g) zinc gluconate or zinc orotate ~~a physiologically acceptable source of assimilable zinc.~~

106. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition contains a ~~physiologically acceptable source of assimilable~~ iron gluconate or iron orotate and a ~~physiologically acceptable source of assimilable sulphur~~.

107. **(Cancelled)**

108. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition contains a ~~physiologically acceptable source of assimilable~~ zinc gluconate or zinc orotate.

109-123. **(Cancelled)**

124. **(Currently Amended)** [[A]] The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition comprises
~~comprising administering to the patient an anti-neoplastic effective amount of a composition comprising:~~

15 to 60 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;

300 to 600 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used; ~~and~~

200 to 1000 parts by weight vitamin C, and

15 to 60 parts by weight of manganese gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used,

the parts by weight referred to being based on the total weight of these ingredients in the composition.

125. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition comprises:

15 to 40 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;

300 to 400 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used; and

300 to 500 parts by weight vitamin C.

126. **(Cancelled)**

127. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 60 parts by weight of sulphur.

128. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 60 parts by weight iron gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable iron other than iron gluconate is used, and 15 to 60 parts by weight of sulphur.

129. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 60 parts by weight zinc gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.

130. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition comprises:

(a) 15 to 40 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;

(b) 350 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used;

(c) 400 parts by weight vitamin C, and

(d) 15 to 40 parts by weight of manganese gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used.

131. **(Cancelled)**

132. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 60 parts by weight of sulphur.

133. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 40 parts by weight iron gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable iron other than iron gluconate is used, and 15 to 40 parts by weight of sulphur.

134. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the composition further comprises 15 to 40 parts by weight zinc gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.

135. **(Currently Amended)** ~~[[A]]~~ The method of treating neoplastic disease in a human or animal patient according to Claim 105 ~~comprising administering to the patient an anti-neoplastic effective amount of a composition comprising as the sole pharmacologically active components:~~

- ~~(a) a physiologically acceptable source of assimilable copper;~~
- ~~(b) salicylic acid or an alkali or alkaline earth metal salt thereof;~~
- ~~(c) vitamin C;~~
- ~~(d) — optionally a physiologically acceptable source of assimilable manganese;~~
- ~~(e) — optionally a physiologically acceptable source of assimilable iron;~~
- ~~(f) — optionally a physiologically acceptable source of assimilable sulphur; and~~
- ~~(h) — optionally a physiologically acceptable source of assimilable zinc;~~

wherein the composition is in the form of an orally administrable unit dosage form.

136-164. **(Cancelled)**

165. **(New)** The method of treating neoplastic disease in a human or animal patient according to claim 105 wherein the composition contains sublimed sulphur.

166. **(New)** The method of treating neoplastic disease in a human or animal patient according to claim 105 wherein the composition comprises as the sole pharmaceutically active components (a)-(d).